157 related articles for article (PubMed ID: 34961766)
1. SATB1, genomic instability and Gleason grading constitute a novel risk score for prostate cancer.
Dumke C; Gemoll T; Oberländer M; Freitag-Wolf S; Thorns C; Glaessgen A; Klooster R; van der Maarel SM; Widengren J; Doehn C; Auer G; Habermann JK
Sci Rep; 2021 Dec; 11(1):24446. PubMed ID: 34961766
[TBL] [Abstract][Full Text] [Related]
2. Revised Gleason grading system is a better predictor of indolent prostate cancer at the time of diagnosis: retrospective clinical-pathological study on matched biopsy and radical prostatectomy specimens.
Giunchi F; Brunocilla E; Borghesi M; Rizzi S; Ricci MS; Romagnoli D; Martorana G; Schiavina R; Fiorentino M
Clin Genitourin Cancer; 2014 Oct; 12(5):325-9. PubMed ID: 24583160
[TBL] [Abstract][Full Text] [Related]
3. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
4. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.
Nordström T; Van Blarigan EL; Ngo V; Roy R; Weinberg V; Song X; Simko J; Carroll PR; Chan JM; Paris PL
Prostate; 2016 Mar; 76(4):339-48. PubMed ID: 26585352
[TBL] [Abstract][Full Text] [Related]
5. Large scale genomic instability as an additive prognostic marker in early prostate cancer.
Pretorius ME; Waehre H; Abeler VM; Davidson B; Vlatkovic L; Lothe RA; Giercksky KE; Danielsen HE
Cell Oncol; 2009; 31(4):251-9. PubMed ID: 19633362
[TBL] [Abstract][Full Text] [Related]
6. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
7. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
8. Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores.
Seisen T; Roudot-Thoraval F; Bosset PO; Beaugerie A; Allory Y; Vordos D; Abbou CC; De La Taille A; Salomon L
World J Urol; 2015 Jun; 33(6):787-92. PubMed ID: 24985552
[TBL] [Abstract][Full Text] [Related]
9. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
[TBL] [Abstract][Full Text] [Related]
10. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
11. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
Beauval JB; Ploussard G; Cabarrou B; Roumiguié M; Ouzzane A; Gas J; Goujon A; Marcq G; Mathieu R; Vincendeau S; Cathelineau X; Mongiat-Artus P; Salomon L; Soulié M; Méjean A; de La Taille A; Rouprêt M; Rozet F;
World J Urol; 2017 Aug; 35(8):1191-1197. PubMed ID: 27987030
[TBL] [Abstract][Full Text] [Related]
12. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion.
Mao L; Yang C; Wang J; Li W; Wen R; Chen J; Zheng J
J Transl Med; 2013 May; 11():111. PubMed ID: 23642278
[TBL] [Abstract][Full Text] [Related]
13. Expression of SATB1 promotes the growth and metastasis of colorectal cancer.
Zhang Y; Tian X; Ji H; Guan X; Xu W; Dong B; Zhao M; Wei M; Ye C; Sun Y; Yuan X; Yang C; Hao C
PLoS One; 2014; 9(6):e100413. PubMed ID: 24971456
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression.
Shukla S; Sharma H; Abbas A; MacLennan GT; Fu P; Danielpour D; Gupta S
PLoS One; 2013; 8(1):e53527. PubMed ID: 23308245
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Gleason score 3 + 4 = 7 prostate cancer with minimal amounts (<6%) vs ≥6% of Gleason pattern 4 tissue in needle biopsy specimens.
Kır G; Seneldir H; Gumus E
Ann Diagn Pathol; 2016 Feb; 20():48-51. PubMed ID: 26750655
[TBL] [Abstract][Full Text] [Related]
16. Elevated fatty acid synthase expression in prostate needle biopsy cores predicts upgraded Gleason score in radical prostatectomy specimens.
Hamada S; Horiguchi A; Kuroda K; Ito K; Asano T; Miyai K; Iwaya K
Prostate; 2014 Jan; 74(1):90-6. PubMed ID: 24108439
[TBL] [Abstract][Full Text] [Related]
17. Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.
Jacobsen F; Taskin B; Melling N; Sauer C; Wittmer C; Hube-Magg C; Kluth M; Simon R; Pehrke D; Beyer B; Steuber T; Thederan I; Sauter G; Schlomm T; Wilczak W; Möller K; Weidemann SA; Burdak-Rothkamm S
BMC Cancer; 2017 Jul; 17(1):504. PubMed ID: 28747165
[TBL] [Abstract][Full Text] [Related]
18. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
20. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis.
Ellis CL; Partin AW; Han M; Epstein JI
J Urol; 2013 Dec; 190(6):2068-73. PubMed ID: 23727307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
